Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | New England Journal of
Medicine Skip to main content The New England Journal of Medicine homepage Advanced …

Introduction: There are growing concerns among European health authorities regarding
increasing prices for new cancer medicines, prices not necessarily linked to health gain and …

Inflammatory diseases, whether caused by excessive stress on certain tissues/parts of the
body or arising from infections accompanying autoimmune or secondary diseases, have …

Background: From October 2018, adalimumab biosimilars could enter the European market.
However, in some countries, such as Netherlands, high discounts reported for the originator …

Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

The importance of the gut microbiota in human health is currently well established. It
contributes to many vital functions such as development of the host immune system …

Aim: Global expenditure on medicines is rising up to 6% per year driven by increasing
prevalence of non-communicable diseases (NCDs) and new premium priced medicines for …

Biological medicines have improved patients' outcomes, but their high costs may limit
access. Biosimilars, alternatives that have demonstrated high similarity in terms of quality …

Nocebo effects encompass negative responses to inert interventions in the research setting
and negative outcomes with active treatments in the clinical research or practice settings …

Background Prevalence and outcomes of coronavirus disease (COVID)-19 in relation to
immunomodulatory medications are still unknown. The aim of the study is to investigate the …